Articles related to LEUKEMIA

Dr. Zackon’s study reveals a stark 18% difference in mortality rates between Black and White CLL patients, underscoring the profound impact of socioeconomic factors on patient outcomes.

The recent study on FLT3 inhibitor monotherapy brings hope to the field of oncology, particularly for patients with high-risk FLT3-mutated AML. Administered at the stage of molecular failure, the therapy has shown encouraging survival rates.

Discover why CPX-351 extends relapse-free survival but does not significantly alter overall survival in younger AML/MDS patients, as revealed by the UK NCRI AML19 trial.

Explore the findings of the A041702 study, presented at the ASCO annual meeting, which investigated the efficacy of two treatment regimens for older patients with CLL. The results, significantly influenced by COVID-19, call for further investigation and long-term follow-up to determine the potential benefits and risks.

This is a golden opportunity to bolster your understanding of AML, implement novel diagnostic strategies, and integrate state-of-the-art treatment plans into your practice. Enrich your professional knowledge, earn valuable CME credits, and most importantly, help improve the lives of your patients.

Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.